Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging

doi:10.1016/j.canlet.2019.03.037

	Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging
	Liu, Shengnan 1,2; Du, Yang2,3,4 ; Ma, He 1; Liang, Qian2,3,4 ; Zhu, Xu 5; Tian, Jie 2,3,4,6,7
发表期刊	CANCER LETTERS
ISSN	0304-3835
	2019
卷号	453 页码:74-83
通讯作者	Ma, He(mahe@bmie.neu.edu.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
摘要	Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after treatment failure with sorafenib. However, there has been no direct systematic comparison of the therapeutic effects of regorafenib and sorafenib against HCC. In this study, we comprehensively compared the therapeutic effects of sorafenib and regorafenib against HCC in vitro and in vivo using multimodality molecular imaging, which can show molecular and cellular differences at early stages. The side effects of sorafenib and regorafenib were also systematically evaluated. The data showed that compared with sorafenib treatment, regorafenib exerted stronger antitumor and antiangiogenic effects and significantly increased the survival rate of HCC mice. Sorafenib but not regorafenib treatment caused body weight loss and liver and kidney dysfunction, while regorafenib but not sorafenib treatment caused hypertension. Our study may provide an experimental basis for the guidance of clinical HCC targeted treatment with regorafenib and sorafenib.
关键词	Hepatocellular carcinoma Regorafenib Sorafenib Molecular imaging Therapeutic effects
DOI	10.1016/j.canlet.2019.03.037
关键词[WOS]	BAY 73-4506 ; APOPTOSIS ; THERAPY ; CANCER ; TUMOR
收录类别	SCI
语种	英语
资助项目	National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022] ; National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022]
项目资助者	National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000467511100007
出版者	ELSEVIER IRELAND LTD
七大方向——子方向分类	其他
引用统计	被引频次：17[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/24586
专题	中国科学院分子影像重点实验室
通讯作者	Ma, He; Zhu, Xu; Tian, Jie
作者单位	1.Northeastern Univ, Sinodutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China 2.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China 3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China 4.Univ Chinese Acad Sci, Beijing 100080, Peoples R China 5.Peking Univ, Sch Oncol, Key Lab Carcinogenesis & Translat Res, Dept Intervent Therapy,Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China 6.Beihang Univ, Sch Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100191, Peoples R China 7.Xidian Univ, Sch Life Sci & Technol, Minist Educ, Engn Res Ctr Mol & Neuro Imaging, Xian 710126, Shaanxi, Peoples R China
第一作者单位	中国科学院自动化研究所
通讯作者单位	中国科学院自动化研究所; 中国科学院分子影像重点实验室
推荐引用方式 GB/T 7714	Liu, Shengnan,Du, Yang,Ma, He,et al. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging[J]. CANCER LETTERS,2019,453:74-83.
APA	Liu, Shengnan,Du, Yang,Ma, He,Liang, Qian,Zhu, Xu,&Tian, Jie.(2019).Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.CANCER LETTERS,453,74-83.
MLA	Liu, Shengnan,et al."Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging".CANCER LETTERS 453(2019):74-83.